These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 21518826

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study.
    Cox IJ, Aliev AE, Crossey MM, Dawood M, Al-Mahtab M, Akbar SM, Rahman S, Riva A, Williams R, Taylor-Robinson SD.
    World J Gastroenterol; 2016 Apr 28; 22(16):4191-200. PubMed ID: 27122669
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Han J, Qin WX, Li ZL, Xu AJ, Xing H, Wu H, Zhang H, Wang MD, Li C, Liang L, Quan B, Yan WT, Shen F, Wu MC, Yang T.
    Clin Chim Acta; 2019 Jan 28; 488():68-75. PubMed ID: 30389456
    [Abstract] [Full Text] [Related]

  • 5. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH, Di Poto C, Wang J, Goerlitz D, Luo Y, Cheema AK, Sarhan N, Soliman H, Tadesse MG, Ziada DH, Ressom HW.
    J Proteome Res; 2012 Dec 07; 11(12):5914-23. PubMed ID: 23078175
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans.
    Ladep NG, Dona AC, Lewis MR, Crossey MM, Lemoine M, Okeke E, Shimakawa Y, Duguru M, Njai HF, Fye HK, Taal M, Chetwood J, Kasstan B, Khan SA, Garside DA, Wijeyesekera A, Thillainayagam AV, Banwat E, Thursz MR, Nicholson JK, Njie R, Holmes E, Taylor-Robinson SD.
    Hepatology; 2014 Oct 07; 60(4):1291-301. PubMed ID: 24923488
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis.
    Tan Y, Yin P, Tang L, Xing W, Huang Q, Cao D, Zhao X, Wang W, Lu X, Xu Z, Wang H, Xu G.
    Mol Cell Proteomics; 2012 Feb 07; 11(2):M111.010694. PubMed ID: 22084000
    [Abstract] [Full Text] [Related]

  • 11. [High-performance liquid chromatography-mass spectrometry-based serum metabolic profiling in patients with HBV-related hepatocellular carcinoma].
    Zhang L, Fan Z, Kang H, Wang Y, Liu S, Shan Z.
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan 30; 39(1):49-56. PubMed ID: 30692066
    [Abstract] [Full Text] [Related]

  • 12. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, Chen Y, Xu J, Zheng S, Li L.
    J Proteome Res; 2012 Feb 03; 11(2):1217-27. PubMed ID: 22200553
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma.
    Comunale MA, Wang M, Rodemich-Betesh L, Hafner J, Lamontagne A, Klein A, Marrero J, Di Bisceglie AM, Gish R, Block T, Mehta A.
    Cancer Epidemiol Biomarkers Prev; 2011 Jun 03; 20(6):1222-9. PubMed ID: 21467232
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical utility of alpha fetoprotein and HCCR-1, alone or in combination, in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Jirun P, Zhang G, Kim HK, Ha SA, Zhongtian J, Shishi Q, Zhuqingqing C, Lei G, Yoo J, Kim S, Park YG, Wang J, Yang Y, Xu Z, Huang Z, Lee YK, Song EY, Kim JW.
    Dis Markers; 2011 Jun 03; 30(6):307-15. PubMed ID: 21725159
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C, Ferrarini A, Zhao Y, Varghese RS, Tu C, Zuo Y, Wang M, Nezami Ranjbar MR, Luo Y, Zhang C, Desai CS, Shetty K, Tadesse MG, Ressom HW.
    Cancer Epidemiol Biomarkers Prev; 2017 May 03; 26(5):675-683. PubMed ID: 27913395
    [Abstract] [Full Text] [Related]

  • 19. Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study.
    Lee CW, Yu MC, Lin G, Chiu JC, Chiang MH, Sung CM, Hsieh YC, Kuo T, Lin CY, Tsai HI.
    World J Surg Oncol; 2020 Jun 03; 18(1):121. PubMed ID: 32493393
    [Abstract] [Full Text] [Related]

  • 20. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
    Passos-Castilho AM, Carvalho VM, Cardozo KH, Kikuchi L, Chagas AL, Gomes-Gouvêa MS, Malta F, de Seixas-Santos Nastri AC, Pinho JR, Carrilho FJ, Granato CF.
    BMC Cancer; 2015 Dec 18; 15():985. PubMed ID: 26680993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.